Press Enter to search · Esc to close
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
The same peptide class that reshaped weight loss is now stacking evidence in kidney protection, fibrosis prevention, and transplant medicine. Here's what the data actually says.
The same drugs reshaping body composition are now generating clinical surprises in both directions — including a side effect nobody saw coming.
A wave of 2025 analyses is dissecting the real mechanisms behind the headline weight loss — and the picture is messier, smarter, and more interesting than the marketing.
GLP-1 receptor agonists keep finding new organs to help. A fresh slate of 2025 evidence maps where the signal is strongest — and where it's still preliminary.
Semaglutide, exendin-4, and tirzepatide are pushing GLP-1 receptor agonists into hepatology and cardiology — while a fresh case report reminds us the safety ledger is still open.
Computational design is pushing peptide therapeutics into oncology, infectious disease, and antimicrobial resistance. The early signals are real — and the caveats matter.
A 109,000-patient meta-analysis sharpens the case that GLP-1 receptor agonists are cardiometabolic drugs, not just weight-loss tools — with concrete numbers on who actually benefits.
GLP-1 receptor agonists keep pushing into new clinical territory. Two 2025 papers — a modeling review for type 1 diabetes and a case report where semaglutide lit up brown fat on a PET scan — hint at what's next.